Blood-Brain Barrier Leakage in Patients with Early Alzheimer Disease
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Purpose To investigate whether the blood-brain barrier (BBB) leaks blood-circulating substances in patients with early forms of Alzheimer disease (AD), and if so, to examine the extent and pattern of leakage. Materials and Methods This study was approved by the local medical ethical committees of the Maastricht University Medical Center and Leiden University Medical Center, and written informed consent was obtained from all subjects. For this pilot study, 16 patients with early AD and 17 healthy age-matched control subjects underwent dynamic contrast material–enhanced magnetic resonance (MR) imaging sequence with dual time resolution for 25 minutes. The Patlak graphical approach was used to quantify the BBB leakage rate and local blood plasma volume. Subsequent histogram analysis was used to determine the volume fraction of the leaking brain tissue. Differences were assessed with linear regression analysis, adjusted for confounding variables. Results The BBB leakage rate was significantly higher in patients compared with that in control subjects in the total gray matter (P < .05) and cortex (P = .03). Patients had a significantly higher volume fraction of the leaking brain tissue in the gray matter (P = .004), normal-appearing white matter (P < .04), deep gray matter (P = .01), and cortex (P = .004). When all subjects were considered, scores on the Mini-Mental State Examination decreased significantly with increasing leakage in the deep gray matter (P = .007) and cortex (P < .05). Conclusion The results of this study showed global BBB leakage in patients with early AD that is associated with cognitive decline. A compromised BBB may be part of a cascade of pathologic events that eventually lead to cognitive decline and dementia. ©RSNA, 2016 Online supplemental material is available for this article. An earlier incorrect version of this article appeared online. This article was corrected on October 24, 2016.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent neuroimaging studies in individuals with mild cognitive impairment (MCI) and early AD reveal BBB breakdown in the hippocampus, including its CA1 and dentate gyrus subfields (421), and several gray and white matter regions (220-222), respectively, before brain atrophy and dementia.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [220]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BBB leakiness is seen both with normal ageing and AD [124,125].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [125]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the BBB disruption and increased permeability have been shown to occur in the early phase of the AD pathology (van de Haar et al., 2016).”
From Exploring the Therapeutic Potential of Phytochemicals in Alzheimer’s Disease: Focus on Polyphenols and Monoterpenes (2022) · cites this paper as van de Haar et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Astrocyte-endothelial interactions at the blood-brain barrier
Abbott, N. J., Rönnbäck, L., & Hansson, E. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1824 · Cited by 5,595
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
Dubois, B., Feldman, H. H., Jacova, C., DeKosky, S. T., Barberger-Gateau, P., Cummings, J., Delacourte, A., Galasko, D., Gauthier, S., Jicha, G., et al. (2007) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70178-3 · Cited by 4,411
Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data
Patlak, C. S., Blasberg, R. G., & Fenstermacher, J. D. (1983) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1983.1 · Cited by 3,567
The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280
Blood-brain barrier breakdown in the aging human hippocampus
Montagne, A., Barnes, S. R., Sweeney, M. D., Halliday, M. R., Sagare, A. P., Zhao, Z., Toga, A. W., Jacobs, R. E., Liu, C. Y., Amezcua, L., et al. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.032 · Cited by 2,102
Research works printed but not linked: 1
- Butman J, 2006, Proceedings of the Fourteenth Meeting of the International Society for Magnetic Resonance in Medicine, 1535
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Blood–brain barrier breakdown is an early biomarker of human cognitive dysfunction
Nation, D. A., Sweeney, M. D., Montagne, A., Sagare, A. P., D’Orazio, L. M., Pachicano, M., Sepehrband, F., Nelson, A. R., Buennagel, D. P., Harrington, M. G., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0297-y · Cited by 1,728
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Montagne, A., Nation, D. A., Sagare, A. P., Barisano, G., Sweeney, M. D., Chakhoyan, A., Pachicano, M., Joe, E., Nelson, A. R., D’Orazio, L. M., et al. (2020) · Nature · doi:10.1038/s41586-020-2247-3 · Cited by 1,281
Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease
Kisler, K., Nelson, A. R., Montagne, A., & Zlokovic, B. V. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.48 · Cited by 1,243
The role of brain vasculature in neurodegenerative disorders
Sweeney, M. D., Kisler, K., Montagne, A., Toga, A. W., & Zlokovic, B. V. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0234-x · Cited by 998
The blood–brain barrier in health and disease: Important unanswered questions
Profaci, C. P., Munji, R. N., Pulido, R. S., & Daneman, R. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20190062 · Cited by 761
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Vascular dysfunction—The disregarded partner of Alzheimer's disease
Sweeney, M. D., Montagne, A., Sagare, A. P., Nation, D. A., Schneider, L. S., Chui, H. C., Harrington, M. G., Pa, J., Law, M., Wang, D. J. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.222 · Cited by 711
“[16] van de Haar HJ, Burgmans S, Jansen JFA, van Osch MJP, van BuchemMA, Muller M, et al.”
Self-citationAlzheimer’s disease: A matter of blood–brain barrier dysfunction?
Montagne, A., Zhao, Z., & Zlokovic, B. V. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20171406 · Cited by 672
“…an early BBB breakdown and vascular dysregulation in AD detectable before cognitive decline and/or other brain pathologies (Montine et al., 2014; Montagne et al., 2015, 2016; Snyder et al., 2015; Sweeney et al., 2015; Iturria-Medina et al., 2016; van de Haar et al., 2016a; Kisler et al., 2017a).”
BackgroundLipids and Alzheimer’s Disease
Kao, Y.-C., Ho, P.-C., Tu, Y.-K., Jou, I.-M., & Tsai, K.-J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041505 · Cited by 485
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
“BBB leakiness is seen both with normal ageing and AD [124,125].”
BackgroundTaoka, T., Ito, R., Nakamichi, R., Nakane, T., Kawai, H., & Naganawa, S. (2024) · Magnetic Resonance in Medical Sciences · doi:10.2463/mrms.rev.2023-0175 · Cited by 383
Zhao, Y., Jaber, V., & Lukiw, W. J. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00318 · Cited by 379
Brain Pericytes As Mediators of Neuroinflammation
Rustenhoven, J., Jansson, D., Smyth, L. C., & Dragunow, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.001 · Cited by 371
Zhan, X., Stamova, B., & Sharp, F. R. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00042 · Cited by 351
“Recent neuroimaging studies in individuals with MCI and early AD have shown BBB breakdown in the hippocampus (Montagne et al., 2015) and several GrayMatter (GM) andWhite Matter (WM) regions (van de Haar et al., 2016a,b, 2017).”
BackgroundNeuroinflammation in Alzheimer’s Disease
Onyango, I. G., Jauregui, G. V., Čarná, M., Bennett, J. P., & Stokin, G. B. (2021) · Biomedicines · doi:10.3390/biomedicines9050524 · Cited by 330
Altered Gut Microbiome Composition and Tryptic Activity of the 5xFAD Alzheimer’s Mouse Model
Brandscheid, C., Schuck, F., Reinhardt, S., Schäfer, K.-H., Pietrzik, C. U., Grimm, M., Hartmann, T., Schwiertz, A., & Endres, K. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-160926 · Cited by 318
Rajeev, V., Fann, D. Y., Dinh, Q. N., Kim, H. A., De Silva, T. M., Lai, M. K. P., Chen, C. L.-H., Drummond, G. R., Sobey, C. G., & Arumugam, T. V. (2022) · Theranostics · doi:10.7150/thno.68304 · Cited by 296
The neuroimmune axis of Alzheimer’s disease
Jorfi, M., Maaser-Hecker, A., & Tanzi, R. E. (2023) · Genome Medicine · doi:10.1186/s13073-023-01155-w · Cited by 292
Taoka, T., Ito, R., Nakamichi, R., Kamagata, K., Sakai, M., Kawai, H., Nakane, T., Abe, T., Ichikawa, K., Kikuta, J., et al. (2022) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01187-5 · Cited by 290
Bacteroides fragilis Lipopolysaccharide and Inflammatory Signaling in Alzheimer’s Disease
Lukiw, W. J. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01544 · Cited by 288
“…toxins from the systemic circulation and CNS but become leaky with age and disease (Montagne et al., 2015; Choi et al., 2016; Minter et al., 2016; Richards et al., 2016; Soenen et al., 2016; van de Haar et al., 2016; Varatharaj and Galea, 2016; Zhan and Davies, 2016; Zhao et al., 2016).”
BackgroundGovindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 275
Glymphatic system impairment in multiple sclerosis: relation with brain damage and disability
Carotenuto, A., Cacciaguerra, L., Pagani, E., Preziosa, P., Filippi, M., & Rocca, M. A. (2022) · Brain · doi:10.1093/brain/awab454 · Cited by 275
Michinaga, S., & Koyama, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030571 · Cited by 263
Bridging barriers: a comparative look at the blood–brain barrier across organisms
O'Brown, N. M., Pfau, S. J., & Gu, C. (2018) · Genes & Development · doi:10.1101/gad.309823.117 · Cited by 263
Unlocking the Power of Exosomes for Crossing Biological Barriers in Drug Delivery
Elliott, R. O., & He, M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13010122 · Cited by 260
Senatorov, V. V., Friedman, A. R., Milikovsky, D. Z., Ofer, J., Saar-Ashkenazy, R., Charbash, A., Jahan, N., Chin, G., Mihaly, E., Lin, J. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8283 · Cited by 257
Hussain, B., Fang, C., & Chang, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.688090 · Cited by 255
Thrippleton, M. J., Backes, W. H., Sourbron, S., Ingrisch, M., van Osch, M. J. P., Dichgans, M., Fazekas, F., Ropele, S., Frayne, R., van Oostenbrugge, R. J., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.013 · Cited by 252
“In an alternative approach, the first pass is sampled at higher temporal resolution with consequently reduced spatial coverage and/or spatial resolution during the early circulatory phases [30].”
BackgroundResultInfluentialSelf-citationBäuerl, C., Collado, M. C., Diaz Cuevas, A., Viña, J., & Pérez Martínez, G. (2018) · Letters in Applied Microbiology · doi:10.1111/lam.12882 · Cited by 238
Taoka, T., & Naganawa, S. (2020) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.26892 · Cited by 238
Blood–brain barrier leakage is more widespread in patients with cerebral small vessel disease
Zhang, C. E., Wong, S. M., van de Haar, H. J., Staals, J., Jansen, J. F. A., Jeukens, C. R. L. P. N., Hofman, P. A. M., van Oostenbrugge, R. J., & Backes, W. H. (2017) · Neurology · doi:10.1212/wnl.0000000000003556 · Cited by 231
Self-citationXia, Y., Prokop, S., & Giasson, B. I. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00460-5 · Cited by 218
de Godoy, M. A., Saraiva, L. M., de Carvalho, L. R. P., Vasconcelos-dos-Santos, A., Beiral, H. J. V., Ramos, A. B., Silva, L. R. D. P., Leal, R. B., Monteiro, V. H. S., Braga, C. V., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.807180 · Cited by 214
Blood-brain barrier impairment and hypoperfusion are linked in cerebral small vessel disease
Wong, S. M., Jansen, J. F. A., Zhang, C. E., Hoff, E. I., Staals, J., van Oostenbrugge, R. J., & Backes, W. H. (2019) · Neurology · doi:10.1212/wnl.0000000000007263 · Cited by 212
Self-citationActivation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Wang, Q., Huang, X., Su, Y., Yin, G., Wang, S., Yu, B., Li, H., Qi, J., Chen, H., Zeng, W., et al. (2022) · Brain · doi:10.1093/brain/awac236 · Cited by 210
Miners, J. S., Schulz, I., & Love, S. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17690761 · Cited by 208
Castelli, V., Benedetti, E., Antonosante, A., Catanesi, M., Pitari, G., Ippoliti, R., Cimini, A., & d’Angelo, M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00132 · Cited by 208
Neurovascular unit impairment in early Alzheimer's disease measured with magnetic resonance imaging
van de Haar, H. J., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Wong, S. M., Hofman, P. A. M., Burgmans, S., Verhey, F. R. J., & Backes, W. H. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.006 · Cited by 207
“The acquisition protocol and analysis method are analogous to a previously described procedure (van de Haar et al., 2016).”
Self-citationIncrease in blood–brain barrier leakage in healthy, older adults
Verheggen, I. C. M., de Jong, J. J. A., van Boxtel, M. P. J., Gronenschild, E. H. B. M., Palm, W. M., Postma, A. A., Jansen, J. F. A., Verhey, F. R. J., & Backes, W. H. (2020) · GeroScience · doi:10.1007/s11357-020-00211-2 · Cited by 205
“…data (diluted MnCl2 stock solution with varying gadobutrol concentrations ranging from 1 to 40 mM and baseline T1 relaxation time comparable to human blood) and in the brain tissue by assuming a linear relationship and using the tissue relaxation time from the T10-map (van de Haar et al. 2016b).”
Self-citationDevelopment of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier
Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202
Modeling Sporadic Alzheimer's Disease in Human Brain Organoids under Serum Exposure
Chen, X., Sun, G., Tian, E., Zhang, M., Davtyan, H., Beach, T. G., Reiman, E. M., Blurton‐Jones, M., Holtzman, D. M., & Shi, Y. (2021) · Advanced Science · doi:10.1002/advs.202101462 · Cited by 200
Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer’s Disease?
Fulop, T., Witkowski, J. M., Bourgade, K., Khalil, A., Zerif, E., Larbi, A., Hirokawa, K., Pawelec, G., Bocti, C., Lacombe, G., et al. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00224 · Cited by 198
Li, Y., Zhang, J., Wan, J., Liu, A., & Sun, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110887 · Cited by 197
Relationship Between Amyloid-β Deposition and Blood–Brain Barrier Dysfunction in Alzheimer’s Disease
Wang, D., Chen, F., Han, Z., Yin, Z., Ge, X., & Lei, P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.695479 · Cited by 197
Chen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 189
Montagne, A., Nikolakopoulou, A. M., Huuskonen, M. T., Sagare, A. P., Lawson, E. J., Lazic, D., Rege, S. V., Grond, A., Zuniga, E., Barnes, S. R., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00073-z · Cited by 188
Dysfunction of the blood–brain barrier in Alzheimer's disease: Evidence from human studies
Kurz, C., Walker, L., Rauchmann, B., & Perneczky, R. (2022) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12782 · Cited by 183
Zimmerman, B., Rypma, B., Gratton, G., & Fabiani, M. (2021) · Psychophysiology · doi:10.1111/psyp.13796 · Cited by 179
Alzheimer’s Disease: The Link Between Amyloid-β and Neurovascular Dysfunction
Solis, Hascup, K. N., & Hascup, E. R. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200473 · Cited by 178
Sandsmark, D. K., Bashir, A., Wellington, C. L., & Diaz-Arrastia, R. (2019) · Neuron · doi:10.1016/j.neuron.2019.06.002 · Cited by 178
Reactive astrocytes: The nexus of pathological and clinical hallmarks of Alzheimer’s disease
Price, B. R., Johnson, L. A., & Norris, C. M. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101335 · Cited by 177
Oksanen, M., Lehtonen, S., Jaronen, M., Goldsteins, G., Hämäläinen, R. H., & Koistinaho, J. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03111-7 · Cited by 153
“1 3 cascade of pathologic events that eventually leads to dementia [61].”
BackgroundThe role of PARP1 in neurodegenerative diseases and aging
Mao, K., & Zhang, G. (2022) · The FEBS Journal · doi:10.1111/febs.15716 · Cited by 172
Takechi, R., Lam, V., Brook, E., Giles, C., Fimognari, N., Mooranian, A., Al-Salami, H., Coulson, S. H., Nesbit, M., & Mamo, J. C. L. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00399 · Cited by 171
Biomarkers for Alzheimer’s Disease Early Diagnosis
Ausó, E., Gómez-Vicente, V., & Esquiva, G. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030114 · Cited by 149
MRI measurements of Blood-Brain Barrier function in dementia: A review of recent studies
Raja, R., Rosenberg, G. A., & Caprihan, A. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.10.034 · Cited by 167
Kann, O., Almouhanna, F., & Chausse, B. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.10.007 · Cited by 150
In vitro modeling of the neurovascular unit: advances in the field
Bhalerao, A., Sivandzade, F., Archie, S. R., Chowdhury, E. A., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00183-7 · Cited by 147
Time to test antibacterial therapy in Alzheimer’s disease
Panza, F., Lozupone, M., Solfrizzi, V., Watling, M., & Imbimbo, B. P. (2019) · Brain · doi:10.1093/brain/awz244 · Cited by 161
Blood–brain barrier link to human cognitive impairment and Alzheimer’s disease
Barisano, G., Montagne, A., Kisler, K., Schneider, J. A., Wardlaw, J. M., & Zlokovic, B. V. (2022) · Nature Cardiovascular Research · doi:10.1038/s44161-021-00014-4 · Cited by 157
Potential Bidirectional Relationship Between Periodontitis and Alzheimer’s Disease
Liccardo, D., Marzano, F., Carraturo, F., Guida, M., Femminella, G. D., Bencivenga, L., Agrimi, J., Addonizio, A., Melino, I., Valletta, A., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00683 · Cited by 156
Central nervous system delivery of molecules across the blood-brain barrier
Gosselet, F., Loiola, R. A., Roig, A., Rosell, A., & Culot, M. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2020.104952 · Cited by 137
Current and emerging avenues for Alzheimer's disease drug targets
Loera‐Valencia, R., Cedazo‐Minguez, A., Kenigsberg, P. A., Page, G., Duarte, A. I., Giusti, P., Zusso, M., Robert, P., Frisoni, G. B., Cattaneo, A., et al. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12959 · Cited by 141
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Van Skike, C. E., Jahrling, J. B., Olson, A. B., Sayre, N. L., Hussong, S. A., Ungvari, Z., Lechleiter, J. D., & Galvan, V. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00570.2017 · Cited by 139
Blood–Brain Barrier Breakdown in Relationship to Alzheimer and Vascular Disease
Lin, Z., Sur, S., Liu, P., Li, Y., Jiang, D., Hou, X., Darrow, J., Pillai, J. J., Yasar, S., Rosenberg, P., et al. (2021) · Annals of Neurology · doi:10.1002/ana.26134 · Cited by 138
Blood-brain barrier integrity in the pathogenesis of Alzheimer’s disease
Huang, Z., Wong, L.-W., Su, Y., Huang, X., Wang, N., Chen, H., & Yi, C. (2020) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2020.100857 · Cited by 126
Zhao, L., Li, Z., Vong, J. S. L., Chen, X., Lai, H.-M., Yan, L. Y. C., Huang, J., Sy, S. K. H., Tian, X., Huang, Y., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18249-3 · Cited by 126
CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients
Skillbäck, T. B., Delsing, L., Synnergren, J., Mattsson, N., Janelidze, S., Nägga, K., Kilander, L., Hicks, R., Wimo, A. B., Winblad, B. G., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.028 · Cited by 139
Brain Metabolic Alterations in Alzheimer’s Disease
Ardanaz, C. G., Ramírez, M. J., & Solas, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073785 · Cited by 125
Pathological changes within the cerebral vasculature in Alzheimer’s disease: New perspectives
Fisher, R. A., Miners, J. S., & Love, S. (2022) · Brain Pathology · doi:10.1111/bpa.13061 · Cited by 131
Shigemoto-Mogami, Y., Hoshikawa, K., & Sato, K. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00494 · Cited by 119
Iyaswamy, A., Thakur, A., Guan, X.-J., Krishnamoorthi, S., Fung, T. Y., Lu, K., Gaurav, I., Yang, Z., Su, C.-F., Lau, K.-F., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01657-4 · Cited by 134
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Liu, C.-Y., Yang, Y., Ju, W.-N., Wang, X., & Zhang, H.-L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00193 · Cited by 131
Liu, Y., Zhong, X., Shen, J., Jiao, L., Tong, J., Zhao, W., Du, K., Gong, S., Liu, M., & Wei, M. (2020) · Brain Research · doi:10.1016/j.brainres.2019.146554 · Cited by 116
The role of peripheral inflammatory insults in Alzheimer’s disease: a review and research roadmap
Walker, K. A., Le Page, L. M., Terrando, N., Duggan, M. R., Heneka, M. T., & Bettcher, B. M. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00627-2 · Cited by 113
Approaches to CNS Drug Delivery with a Focus on Transporter-Mediated Transcytosis
Abdul Razzak, R., Florence, G. J., & Gunn-Moore, F. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123108 · Cited by 112
Blood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Nagaraj, S., Zoltowska, K. M., Laskowska-Kaszub, K., & Wojda, U. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2018.10.008 · Cited by 121
Walker, J. M., Dixit, S., Saulsberry, A. C., May, J. M., & Harrison, F. E. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.01.004 · Cited by 110
Amin, F. U., Hoshiar, A. K., Do, T. D., Noh, Y., Shah, S. A., Khan, M. S., Yoon, J., & Kim, M. O. (2017) · Nanoscale · doi:10.1039/c7nr00772h · Cited by 118
Vascular Hypothesis of Alzheimer Disease: Topical Review of Mouse Models
Scheffer, S., Hermkens, D. M. A., van der Weerd, L., de Vries, H. E., & Daemen, M. J. A. P. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.120.311911 · Cited by 102
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno-Gonzalez, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 102
The glymphatic system and meningeal lymphatics of the brain: new understanding of brain clearance
Yankova, G., Bogomyakova, O. B., & Тулупов, А. А. (2021) · Reviews in the Neurosciences · doi:10.1515/revneuro-2020-0106 · Cited by 118
Endothelial Mitochondrial Dysfunction in Cerebral Amyloid Angiopathy and Alzheimer’s Disease
Parodi-Rullán, R., Sone, J. Y., & Fossati, S. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-190357 · Cited by 106
“Along with decreased mitochondrial content in CECs [82], brain biopsies [82], and MRI of AD patients [83] have shown BBB dysfunction and leakage.”
Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116
Sun, M., Ma, K., Wen, J., Wang, G., Zhang, C., Li, Q., Bao, X., & Wang, H. (2020) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190872 · Cited by 113
Engineered nanomaterials that exploit blood-brain barrier dysfunction for delivery to the brain
Wu, J. R., Hernandez, Y., Miyasaki, K. F., & Kwon, E. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114820 · Cited by 97
The role of the blood–brain barrier during neurological disease and infection
Patabendige, A., & Janigro, D. (2023) · Biochemical Society Transactions · doi:10.1042/bst20220830 · Cited by 112
Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease
Di Pardo, A., Amico, E., Scalabrì, F., Pepe, G., Castaldo, S., Elifani, F., Capocci, L., De Sanctis, C., Comerci, L., Pompeo, F., et al. (2017) · Scientific Reports · doi:10.1038/srep41316 · Cited by 103
An Integrated View on Vascular Dysfunction in Alzheimer’s Disease
Klohs, J. (2019) · Neurodegenerative Diseases · doi:10.1159/000505625 · Cited by 111
Non‐contrast MR imaging of blood‐brain barrier permeability to water
Lin, Z., Li, Y., Su, P., Mao, D., Wei, Z., Pillai, J. J., Moghekar, A., van Osch, M. J. P., Ge, Y., & Lu, H. (2018) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27141 · Cited by 111
Measuring water exchange across the blood-brain barrier using MRI
Dickie, B., Parker, G. J. M., & Parkes, L. M. (2019) · Progress in Nuclear Magnetic Resonance Spectroscopy · doi:10.1016/j.pnmrs.2019.09.002 · Cited by 111
Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion
Faridar, A., Thome, A. D., Zhao, W., Thonhoff, J. R., Beers, D. R., Pascual, B., Masdeu, J. C., & Appel, S. H. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa112 · Cited by 104
Alzheimer's disease pathophysiology in the Retina
Gaire, B. P., Koronyo, Y., Fuchs, D.-T. S., Shi, H., Rentsendorj, A., Danziger, R., Vit, J., Mirzaei, N., Doustar, J., Sheyn, J., et al. (2024) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2024.101273 · Cited by 110
Carter, C. J., France, J., Crean, S., & Singhrao, S. K. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00408 · Cited by 95
“Disruption of the BBB is an early feature of AD (van de Haar et al., 2016), and P. gingivalis may be one of the many factors contributing to this adverse outcome.”
Gullotta, G. S., Costantino, G., Sortino, M. A., & Spampinato, S. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119144 · Cited by 110
Metadata
- Authors
- van de Haar, H. J., Burgmans, S., Jansen, J. F. A., van Osch, M. J. P., van Buchem, M. A., Muller, M., Hofman, P. A. M., Verhey, F. R. J., & Backes, W. H.
- Affiliations
- Maastricht University Medical Centre (NL)
- Leiden University Medical Center (NL)
- Leiden University (NL)
- ORCID
- Venue
- Radiology
- Published
- 2016-11
- Volume
- 281
- Issue
- 2
- Pages
- 527-535
- ISSN
- 0033-8419 (ISSN-L)
- 1527-1315
- OpenAlex
- W2415637550
- Cited by
- 601
- References
- 32
- Citations by year
- 2026: 37 · 2025: 56 · 2024: 66 · 2023: 65 · 2022: 81 · 2021: 89 · 2020: 64 · 2019: 50 · 2018: 42 · 2017: 36 · 2016: 13
- FWCI
- 25.63
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Radiology (publishedVersion)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, other-oa)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Funders
- Radiological Society of North America
- Internationale Stichting Alzheimer Onderzoek (10553)
- Topics
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- blood-brain barrier disruption, early Alzheimer's disease, dynamic contrast-enhanced MRI, Patlak graphical analysis, plasma volume, gray matter, normal-appearing white matter, deep gray matter, cognitive decline, Mini-Mental State Examination
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Blood Volume, Blood-Brain Barrier, Contrast Media, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Pilot Projects, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.